Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

Bamco Inc. NY bought a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,600 shares of the biotechnology company’s stock, valued at approximately $1,113,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Jones Financial Companies Lllp raised its position in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in Ascendis Pharma A/S during the third quarter valued at about $74,000. Farther Finance Advisors LLC grew its stake in Ascendis Pharma A/S by 115.3% in the third quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares during the last quarter. Toth Financial Advisory Corp grew its stake in Ascendis Pharma A/S by 33.7% in the third quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 150 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 15.2% in the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 97 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $231.02 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $124.06 and a fifty-two week high of $248.60. The company has a market cap of $14.32 billion, a PE ratio of -52.50 and a beta of 0.43. The business has a 50-day simple moving average of $224.60 and a two-hundred day simple moving average of $211.59.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $285.35 million. On average, sell-side analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on ASND. Oppenheimer increased their price target on shares of Ascendis Pharma A/S from $246.00 to $262.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Wedbush increased their target price on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Finally, Evercore restated an “outperform” rating and issued a $324.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $289.89.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.